Search
Ardeparin Action Pathway
smpdb.ca/view/SMP0000275Drug actionArdeparin binds and increases antithrombin III activity and inactivates thrombin, factor Xa and coagulation factors XIIa, XIa, plasmin and kallikrein to prevent clot formation. … These properties increase ardeparin's bioavailability and give a more predictable anticoagulant activity.
Enzymes: Coagulation factor IX, Coagulation factor VIIIEptifibatide Action Pathway (new)
smpdb.ca/view/SMP0126461Drug actionThe conformational change also prevents the binding of the von Willebrand factor to the platelets, which also prevents aggregation and adhesion. … It is administered intravenously and can act to decrease platelet aggregation for up to two days after administration.
Abciximab Action Pathway
smpdb.ca/view/SMP0121127Drug actionThe conformational change also prevents the binding of von Willebrand factor to the platelets, which also prevents aggregation and adhesion. … It is administered intravenously, and can act to decrease platelet aggregation for up to two days after administration.
Tirofiban Action Pathway (new)
smpdb.ca/view/SMP0126470Drug actionIt is administered intravenously and acts as an antagonist of the platelet glycoprotein IIb/IIIa receptor, this receptor is responsible for platelet aggregation in order to form a thrombus, without this
Fenofibrate Metabolism Pathway
smpdb.ca/view/SMP0125319MetabolicFenofibrate is a peroxisome proliferator receptor alpha activator used to lower LDL-C, total-C, triglycerides, and Apo B, while increasing HDL-C in hypercholesterolemia, dyslipidemia, and hypertriglyceridemia … Reduction of the carbonyl group is primarily mediated by CBR1 and minorly by AKR1C1, AKR1C2, AKR1C3, and AKR1B1. 5-25% of a dose of fenofibrate is eliminated in the feces, while 60-88% is eliminated in
Bemiparin Action Pathway
smpdb.ca/view/SMP0126156Drug actionFactor Xa is necessary for the formation of a thrombus, it acts to increase coagulation by converting prothrombin to thrombin. … The mechanism of action of the antithrombotic acts mainly on factor Xa to prevent thromboembolism following surgery.
Drugs: CalciumEnzymes: Coagulation factor XSulodexide Action Pathway
smpdb.ca/view/SMP0126173Drug actionIts mechanism of action inhibits coagulation by inhibiting antithrombin III thus stopping the conversion of prothrombin and thrombin. … Doing that also inhibits the conversion of fibrinogen to fibrin halting the clotting factor. Sulodexide is administered via oral, intravenous or intramuscular, it is mainly metabolized by the liver.
Drugs: CalciumEnzymes: Coagulation factor XReviparin Action Pathway
smpdb.ca/view/SMP0126278Drug actionReviparin is a low molecular weight heparin derived from a pig's intestinal mucus and used to prevent thromboembolism.
Enzymes: Coagulation factor XArdeparin Action Pathway (new)
smpdb.ca/view/SMP0126657Drug actionArdeparin acts on antithrombin III, which leads to the inactivation of factor Xa and thrombin inhibiting thrombosis. It is administered subcutaneously and travels to its target in the bloodstream. … Due to its anticoagulant nature herbs and supplements with similar activity should be avoided such as ginseng, ginkgo, ginger and garlic.
Enzymes: Coagulation factor XAxitinib Action Pathway
smpdb.ca/view/SMP0126901Drug actionIt belongs to the class of drugs known as tyrosine kinase inhibitors, specifically targeting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3). … Axitinib is recognized for its high potency compared to earlier VEGFR inhibitors and is available in oral formulations under the brand name Inlyta®.
Enzymes: Coagulation factor X